Uppsala, Sweden 12 January 2017. OssDsign AB, a Swedish designer, manufacturer and distributor of next generation implants for cranial and facial reconstruction, today announced it has entered new commercial partnerships covering distribution of its products in Italy, Spain, Switzerland, Austria and The Netherlands.
OssDsign‘s lead products – OSSDSIGN® Cranial and OSSDSIGN® Facial – are already on sale in Germany, the UK and the Nordic region, as well as selected non-European markets including Singapore and Israel. The Company is preparing for its first product launch in the US, which is anticipated during the first quarter of 2017, and is also undertaking regulatory and commercial activities in Japan.
OssDsign’s commercial strategy is focused on building sales of its innovative products through a combination of its internal sales organisation and distribution partnerships, and the Company is well-funded to support this strategy.
Anders Lundqvist, CEO of OssDsign, said: “We are very pleased to increase our commercial footprint in Europe as we work to become the leading provider of regenerative implants for cranial and facial reconstruction. We now have experienced and well-motivated teams in place to execute our European strategy and bring OssDsign products closer to the surgeons and patients who will ultimately benefit from them.”
For further information, please contact:
Anders Lundqvist, CEO, OssDsign AB
Phone: +46 73 206 98 08, email: email@example.com
OssDsign is a Swedish medtech company dedicated to creating regenerative implants for improved healing of bone defects and deficits in skull, facial and other types of surgery. OssDsign has successfully launched its first patient specific products OSSDSIGN® Cranial and OSSDSIGN® Facial in Germany, the UK and the Nordic countries, and further global market expansion is ongoing.
By combining clinical insight with proprietary material technology and patient adapted design, OssDsign supplies an expanding range of tailored solutions for cranial repair and facial bone reconstruction. OssDsign’s technology is the result of collaboration between clinical researchers at the Karolinska University Hospital, Stockholm, and material science experts at the Ångström Laboratory at Uppsala University. For more information: www.ossdsign.com